Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHT™ – now ...

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTtm ? now ...

Perspectum today released the results of a multinational study showing that LiverMultiScan can reduce liver biopsies, lead to fewer specialist consultations, and improve the rate of diagnosis for ...

VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, ...

Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. ("CytoDyn" or the "Company"). On February 24, 2025 ...

IDAHO FALLS – A celebration of Scottish heritage and the country’s most famous poet is happening next month at The Waterfront ...

If you could only eat at one restaurant in Birmingham for the rest of your life, which would it be? We asked; readers answered.

With haute cuisine and polished service, Hermosa Beach’s Vin Folk offers diners a taste of fine dining—minus the sky-high ...

Sequana Medical announces 2024 Full Year Results and 2025 Outlookalfapump® – US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...